Program offers lectures and workshops on how to develop a solution – a new product or drug – and what inventors need to understand about business and finance when targeting on to exploit the commercial value of their solutions.
Together with European SPARK network we organize joint webinars. An online education platform is also being developed with European SPARK network in a project lead by SPARK Finland and Tampere University.
Jointly with active European SPARK programmes, we offer an education platform, where topics on product development, business building and its financing in health tech and life science space can be studied. Currently the platform is open to SPARK Finland teams, but will soon be opened also to participating European SPARK programmes.
Lectures and workshops are open for anyone interested in how to develop a new solution in health tech and life science space, and how to exploit the commercial value that it creates. Students can get also graduate and post-graduate level credits for their studies.
The lecture series is part of the BBT.MJS.147 Health Technology and Life Science R&D (5 ECTS) course organized in Tampere University by SPARK Finland. The course contains prerecorded video lectures, live webinars and discussion related to the topics of the course as well as course assignment which is mandatory for getting credits from the course.
Lectures and meetings are open for all interested. Enrollment to the 5 ECTS course for students from SPARK Finland associated organizations will be open 15 – 31 December, 2022. More information on enrollment attached.
The course starts in January 2023 with introduction and practical arrangements related to the course.
Introduction to life science R&D, Product development process, Product market fit, Design thinking in R&D projects, IPR issues, Regulation and quality, Clinical trials, Proof-of-concept and relevance, Project and process management
The lecture series is part of the BBT.MJS.141 Health Technology and Life Science Business (5 ECTS) course organized in Tampere University by SPARK Finland. The course contains prerecorded video lectures, live webinars and discussion related to the topics of the course as well as course assignment which is mandatory for getting credits from the course.
Lectures and meetings are open for all interested.
The course starts in September 2023 with introduction and practical arrangements related to the course.
The webinars will take place once a month on Wednesdays at 17-18 (Finnish time). The webinars cover various topics in product development and business building in health tech and life science (Drug, Medical Device & Diagnostic Development).
The webinar series is open to all SPARKees, SPARK mentors, and students and staff of SPARK associated organizations.
Previous webinar series:
Spring 2023
Autumn 2022
Spring 2022
Autumn 2021
Spring 2021
See events for lecture dates and details.
Notion: The lecture dates will be updated throughout the year.
Please follow event calendar or contact SPARK Finland for more information.
Dohse H (2016). Starting a medical device company: everything you need to know. Medical Design & Outsourcing.
Heinonen T, Sorvisto W, Sorvisto P, Väisänen J (2018). SPARK partnering with Business Schools – Case Finland Report. In collaboration with SPARK Global network.
Letscher T & Wrigley BA. The Key to Successfully Starting a Medical Technology Company. Cath Lab Digest Volume 11 – Issue 3 – March, 2003.
Rodríguez Fernández C. 5 Expert Tips to Success When Building a Biotech Startup. Article on 23.08.2016 at LABIOTECH.eu
Tajonar A. How to start a biotech company. Mol Biol Cell. 2014 Nov 1; 25(21): 3280–3283.
Baell J, Walters MA. Chemistry: Chemical con artists foil drug discovery. Nature. 2014;513(7519):481-3. Epub 2014/09/26.
Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-3.
Dosa PI, Georg GI, Gurvich VJ, Hawkinson JE, Walters MA, Wong HL. From HTS to Phase I: the Institute for Therapeutics Discovery and Development at the University of Minnesota. Comb Chem High Throughput Screen. 2014;17(3):231-40.
Everitt JI. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. Toxicologic pathology. 2015;43(1):70-7.
Lombardino JG, Lowe JA, 3rd. The role of the medicinal chemist in drug discovery–then and now. Nature reviews Drug discovery. 2004;3(10):853-62.
Manns MP. [Role of academic medicine for innovations in development of drugs and biomedicine technology]. Dtsch Med Wochenschr. 2013;138(40):1993-4.
Pelkonen O, Turpeinen M, Raunio H. In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. Clinical pharmacokinetics. 2011;50(8):483-91.
Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nature reviews Drug discovery. 2011;10(9):712.
Pritchard JF, Jurima-Romet M, Reimer ML, Mortimer E, Rolfe B, Cayen MN. Making better drugs: Decision gates in non-clinical drug development. Nature reviews Drug discovery. 2003;2(7):542-53.
Prueksaritanont T, Tang C. ADME of biologics-what have we learned from small molecules? The AAPS journal. 2012;14(3):410-9.
Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011;10(7):507-19.
van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nature reviews Drug discovery. 2003;2(3):192-204.
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical research. 2005;22(1):11-23.
Vaudano E. The innovative medicines initiative: a public private partnership model to foster drug discovery. Comput Struct Biotechnol J. 2013;6:e201303017.
Scott CT, Borgelt EL, Lee SS. The time is ripe for an ethics of entrepreneurship. Nature biotechnology. 2014;32(4):316-8.
Ford D, Nelsen B. The view beyond venture capital. Nature biotechnology. 2014;32(1):15-23.
Toner M, Tompkins RG. Invention, innovation, entrepreneurship in academic medical centers. Surgery. 2008;143(2):168-71.
Van Dyke M. How much risk are you prepared to take? Nature biotechnology. 2012;30(9):821-4.
Kirschenbaum SR. Patenting basic research: myths and realities. Nat Neurosci. 2002;5 Suppl:1025-7.
Lei Z, Juneja R, Wright BD. Patents versus patenting: implications of intellectual property protection for biological research 2009:[36-40 pp.]. Available from:
Murray F, Stern S. Do formal intellectual property rights hinder the free flow of scientific knowledge?: An empirical test of the anti-commons hypothesis. Journal of Economic Behavior & Organization. 2007;63(4):648-87
Reitzig M. Strategic management of intellectual property. MIT Sloan Management Review. 2004;45(3):35-40
Rose LM, Everts M, Heller C, Burke C, Hafer N, Steele S. Academic medical product development: an emerging alliance of technology transfer organizations and the CTSA. Clin Transl Sci. 2014;7(6):456-64.
Abudi G. The Five Stages of Project Team Development. The.Project.Management.Hut [Internet]. 2010 May 7, 2015:[7pgs p.].
Zappe H. Innovation: Bridging the market gap. Nature. 2013;501(7468):483-5. Epub 2013/09/28.
Capponi L, Trinh-Shevrin C, Cronstein BN, Hochman JS. A public-private partnership: the New York University-Health and Hospitals Corporation Clinical and Translational Science Institute. Clin Transl Sci. 2012;5(3):223-5.
Luijten PR, van Dongen GA, Moonen CT, Storm G, Crommelin DJ. Public-private partnerships in translational medicine: concepts and practical examples. J Control Release. 2012;161(2):416-21.
Murphy DG, Goldman M, Loth E, Spooren W. Public-private partnership: a new engine for translational research in neurosciences. Neuron. 2014;84(3):533-6.
Peng X. University spin-offs: opportunity or challenge? Nat Mater. 2006;5(12):923-5.
Begley CG. Six red flags for suspect work. Nature. 2013;497(7450):433-4.
Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-3.
Bissell M. Reproducibility: The risks of the replication drive. Nature. 2013;503(7476):333-4.
Everitt JI. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. Toxicologic pathology. 2015;43(1):70-7.
Freedman LP, Inglese J. The increasing urgency for standards in basic biologic research. Cancer research. 2014;74(15):4024-9.
Peers IS, Ceuppens PR, Harbron C. In search of preclinical robustness. Nature reviews Drug discovery. 2012;11(10):733-4.
Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nature reviews Drug discovery. 2011;10(9):712.
Aguilar A, Magnien E, Thomas D. Thirty years of European biotechnology programmes: from biomolecular engineering to the bioeconomy. N Biotechnol. 2013;30(5):410-25.
Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840-2. Epub 2008/06/13.
Duda GN, Grainger DW, Frisk ML, Bruckner-Tuderman L, Carr A, Dirnagl U, Einhaupl KM, Gottschalk S, Gruskin E, Huber C, June CH, Mooney DJ, Rietschel ET, Schutte G, Seeger W, Stevens MM, Urban R, Veldman A, Wess G, Volk HD. Changing the mindset in life sciences toward translation: a consensus. Sci Transl Med. 2014;6(264):264cm12. Epub 2014/11/28.
Gehr S, Garner CC. Rescuing the Lost in Translation. Cell. 2016; 165(4): 765-770.
Germann PG, Schuhmacher A, Harrison J, Law R, Haug K, Wong G. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective. Hum Genomics. 2013;7:5.
Goldman M. The innovative medicines initiative: a European response to the innovation challenge. Clin Pharmacol Ther. 2012;91(3):418-25.
Klech H, Brooksbank C, Price S, Verpillat P, Buhler FR, Dubois D, Haider N, Johnson C, Linden HH, Payton T, Renn O, See W. European initiative towards quality standards in education and training for discovery, development and use of medicines. Eur J Pharm Sci. 2012;45(5):515-20.
Knowlton AA, Rainwater JA, Chiamvimonvat N, Bonham AC, Robbins JA, Henderson S, Meyers FJ. Training the translational research teams of the future: UC Davis-HHMI Integrating Medicine into Basic Science program. Clin Transl Sci. 2013;6(5):339-46.
Kocher R, Roberts B. The calculus of cures. The New England journal of medicine. 2014;370(16):1473-5.
Ledford H. Biotech boot camp. Nature. 2015;519(7544):402-5.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature reviews Drug discovery. 2010;9(3):203-14.
Schubert C. Innovation: The big idea of technology transfer. Nature. 2012;484(7393):277-8. Epub 2012/04/17.
Sheft J. Technology transfer and idea commercialization. Nature biotechnology. 2008;26(6):711-2.
Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011;10(7):507-19.
Wright BD, Drivas K, Lei Z, Merrill SA. Technology transfer: Industry-funded academic inventions boost innovation. Nature. 2014;507(7492):297-9. Epub 2014/03/22.
Bouchie A, Allison M, Webb S, DeFrancesco L. Nature Biotechnology’s academic spinouts of 2013. Nature biotechnology. 2014;32(3):229-38.
Bouchie A, DeFrancesco L. Nature Biotechnology’s academic spinouts of 2014. Nature biotechnology. 2015;33(3):247-55.
Sorkness CA, Pfund C, Asquith P, Drezner MK. Research mentor training: initiatives of the University of Wisconsin Institute for Clinical and Translational Research. Clin Transl Sci. 2013;6(4):256-8.